Most patients across both cohorts were male (cohort 1, 74.1% cohort 2, 75.0%) and White ( 83.9% 82.4%). The mean age of patients in the ASCT cohort was 65.2 years (standard deviation, ± 9.51), compared with 60.5 years (SD, ± 9.75) for those in the non-ASCT cohort. Kaplan-Meier survival analysis was done using a log-rank test for time-to-event analyses to estimate long-term survival rates. An index event was defined as time of initial diagnosis, and investigators selected a designated time window of 6000 days.Īnalysis of mortality risk was conducted with Cox regression modeling. To minimize potential confounding factors, investigators utilized propensity score matching. Investigators gathered and analyzed demographic, laboratory work, and outcomes data. In cohort 2, patients needed to have an ICD-10 diagnosis of MCL at presentation without ICD-10 diagnoses of stem cell transplant or other leukemia or lymphoma. Patients in cohort 1 were required to have ICD-10 diagnoses of MCL and stem cell transplant without other ICD-10 leukemia or lymphoma diagnoses. The TriNetX web-based research data registry and querying tool was utilized to conduct the retrospective study. Moreover, investigators aimed to analyze potential prognostic indicators currently used for risk stratification in MCL and to examine survival and mortality data for patients who received these 2 approaches. To better understand the effect of ASCT on real-world outcomes of this patient population, investigators used a multi-institutional longitudinal clinical database tool to evaluate patient characteristics and outcomes in patients who did or did not receive consolidation ASCT. For the frontline treatment of patients with this disease, induction chemoimmunotherapy with or without consolidative ASCT is typically considered. Historically, MCL has been linked with poor response to standard-of-care chemotherapy. “Based on our data, we would recommend ASCT consolidation for MCL as first-line therapy.” “ suggest that ASCT consolidation confers a survival benefit in patients able to tolerate it,” study authors Jonathan Shakesprere, MD, and Salahuddin Safi, MD, both of West Virginia University School of Medicine, Morgantown, West Virginia, wrote in a poster. Notably, 10 patients from each cohort were excluded from the mortality results due to an outcome occurring outside the time window. Moreover, the survival probability at the end of the time window was 64.49% for those who underwent ASCT vs 31.56% for those who did not (x2 = 15.079 P =. Following propensity score matching, 607 patients were selected for each cohort.įindings showed that 105 patients in the ASCT cohort died within the study’s selected 6000-day time window, translating to a mortality risk of 17.298% 153 patients in the non-ASCT cohort died during that window, equating to a mortality risk of 25.206%. Investigators identified 745 patients with MCL who met the inclusion criteria for the ASCT cohort (cohort 1) and 5245 patients for the non-ASCT cohort (cohort 2).
All rights reserved.Consolidative autologous stem cell transplant (ASCT) was associated with a statistically significant lower overall mortality risk and higher overall survival (OS) probability in patients with mantle cell lymphoma (MCL) vs those who did not receive consolidation, according to data from a real-world analysis presented at the 2023 Transplantation and Cellular Therapy Meetings. Finally, our current approach to ES is included along with a proposed treatment algorithm for the management of this complication.Īutologous graft-versus-host disease Engraftment syndrome Lymphoma Multiple myeloma POEMS.Ĭopyright © 2015 American Society for Blood and Marrow Transplantation. Furthermore, we discuss the proposed risk factors, etiology, and clinical relevance of ES. Here, we present a comprehensive review of ES in all documented disease settings. Given its pleiotropic clinical presentation, the transplant field has struggled to clearly define ES and related syndromes.
#AUTOLOGOUS STEM CELL TRANSPLANT ICD 10 SKIN#
ES may include noninfectious fever, skin rash, diarrhea, hepatic dysfunction, renal dysfunction, transient encephalopathy, and capillary leak features, such as noncardiogenic pulmonary infiltrates, hypoxia, and weight gain with no alternative etiologic basis other than engraftment. Engraftment syndrome (ES) encompasses a continuum of periengraftment complications after autologous hematopoietic stem cell transplantation.
0 kommentar(er)
